Suzanne Gilberg-Lenz
Beverly Hills, CANPI 1467492041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $200,346 of the $316,430 with a category attached, or 63.3%. Bsn Medical Inc accounts for 98.0% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2021 at $200,978 and has fallen 99.7% since, to $544 in 2025.
Across 316 payments — averaging $1001.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bsn Medical Inc$310K
- AbbVie$2K
- Daiichi Sankyo Inc.$874
- AMAG Pharmaceuticals, Inc.$416
- Scynexis, Inc.$407
- Evofem Biosciences, Inc.$398
- plus $3K from 36 others
What the payments were for
- Consulting fees$3240%
- Speaking & faculty fees$200,34663%
- Food & beverage$115,66937%
- Education$920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bsn Medical Inc | 7 | $310,000 |
| AbbVie(2 entities) | 92 | $1,725 |
| Daiichi Sankyo Inc. | 42 | $874 |
| AMAG Pharmaceuticals, Inc. | 8 | $416 |
| Scynexis, Inc. | 4 | $407 |
| Evofem Biosciences, Inc. | 32 | $398 |
| Therapeuticsmd, Inc. | 17 | $340 |
| Mayne Pharma Commercial LLC | 12 | $300 |
| Coopersurgical, Inc. | 15 | $290 |
| Pfizer | 14 | $254 |
| Bayer | 9 | $197 |
| Sumitomo Pharma America, Inc. | 9 | $161 |
| Myovant Sciences Inc. | 10 | $159 |
| Exeltis, USA Inc. | 4 | $88 |
| Astellas Pharma US Inc | 3 | $73 |
| Exact Sciences | 3 | $67 |
| Hologic Sales And Service, LLC | 3 | $57 |
| Baxter Healthcare | 1 | $49 |
| Vertical Pharmaceuticals, LLC | 3 | $46 |
| Duchesnay USA Incorporated | 2 | $44 |
| Meditrina | 2 | $44 |
| Merck | 2 | $42 |
| Agile Therapeutics, Inc. | 2 | $35 |
| Lilly USA, LLC | 1 | $33 |
| Amgen | 1 | $29 |
| Lupin Inc. | 2 | $29 |
| Heartflow, Inc. | 1 | $27 |
| Biogen | 1 | $26 |
| Shield Therapeutics Inc | 1 | $25 |
| Millicent US Inc | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Medicem Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $17 |
| Axonics, Inc. | 1 | $16 |
| Minerva Surgical, Inc | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
| BD | 1 | $13 |
| Mycovia Pharmaceuticals, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Ascend Therapeutics US, LLC | 1 | $12 |
| Covidien LP | 1 | $11 |
| Channel Medsystems, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOBST FORMEN AMBITION$100,000
- ACTIMOVE$100,000
- CUTIMED SORBACT$44,000
- VYLEESI$324
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImvexxyEstradiol | 37 | $18,051 |
| PrometriumProgesterone, Micronized | 16 | $6,675 |
| Estradiol | 57 | $6,185 |
| PremproEstrogen,con/M-Progest Acet | 15 | $3,614 |
| Vivelle-DotEstradiol | 17 | $2,810 |
| Estradiol (Twice Weekly)Estradiol | 29 | $2,159 |
| ProgesteroneProgesterone, Micronized | 42 | $1,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Therapeuticsmd, Inc.Imvexxy | $340 | $18,05137 claims |
| PfizerPrempro | $254 | $3,61415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.